An update on the Second Sight Medical Products (NASDAQ:EYES) saga comes to us by way of IEEE Spectrum, offering a cautionary tale for the developers of cutting-edge implants and the patients who place their faith in them. The future remains cloudy for the Los Angeles–based developer of the Argus 2s retinal prosthesis system, which is […]